Search

Your search keyword '"Jacobsen, E."' showing total 2,448 results
Start Over Author "Jacobsen, E."
2,448 results on '"Jacobsen, E."'

1. Dynamic Rating of Transmission Cables

Author

Jacobsen, E., Nielsen, J.F., Nielzen, S.B., Salwin, S.T., Jensen, A.S., Nolden, W., Cohnen, K. H., Mohrs, A., and Seier, S.

Published
2010

3. PB0945 Effect of Drug Interactions with Apixaban on Clinical Outcomes in Cancer Patients with Venous Thromboembolism

Author

Svalastoga, M., primary, Larsen, T., additional, Brekke, J., additional, Enden, T., additional, Frøen, H., additional, Garresori, H., additional, Jacobsen, E., additional, Porojnicu, A., additional, Ree, A., additional, Torfoss, D., additional, Velle, E., additional, Skuterud Wik, H., additional, Ghanima, W., additional, Sandset, P., additional, and Dahm, A., additional

Published
2023
Full Text
View/download PDF

4. OC 03.5 Arterial Events in Cancer Patients Treated with Apixaban for Venous Thrombosis

Author

Larsen, T., primary, Svalastoga, M., additional, Brekke, J., additional, Enden, T., additional, Frøen, H., additional, Garresori, H., additional, Jacobsen, E., additional, Paulsen, P., additional, Porojnicu, A., additional, Ree, A., additional, Torfoss, D., additional, Velle, E., additional, SkuterudWik, H., additional, Ghanima, W., additional, Sandset, P., additional, and Dahm, A., additional

Published
2023
Full Text
View/download PDF

6. Positive Allosteric Modulators of the α7 Nicotinic Acetylcholine Receptor: SAR Investigation Around PNU-120596

Author

Acker, Brad A., primary, Badescu, Valentina O., additional, Berkenpas, Mitchell B., additional, Groppi, Vincent E., additional, Hajós, Mihaly, additional, Higdon, Nicole R., additional, Hurst, Raymond S., additional, Jon Jacobsen, E., additional, Margolis, Brandon J., additional, McWhorter, William W., additional, Myers, Jason K., additional, Piotrowski, David W., additional, Rogers, Bruce N., additional, Sarapa, Dusan, additional, Vetman, Tatiana N., additional, Walker, Daniel P., additional, Wall, Theron M., additional, Wilhite, David M., additional, Wishka, Donn G., additional, Xu, Wenjian, additional, and Yates, Karen M., additional

Published
2023
Full Text
View/download PDF

8. The relationship between alcohol use and dementia in adults aged more than 60 years: a combined analysis of prospective, individual-participant data from 15 international studies

Author

Mewton, L., Visontay, R., Hoy, N., Lipnicki, D. M., Sunderland, M., Lipton, R. B., Guerchet, M., Ritchie, K., Najar, J., Scarmeas, N., Kim, K.-W., Riedel Heller, S., Boxtel, M. van, Jacobsen, E., Brodaty, H., Anstey, K. J., Haan, M., Scazufca, M., Lobo, E., and Sachdev, P. S.

Abstract

Methods: Individual participant data meta-analysis of 15 prospective epidemiological cohort studies from countries situated in six continents. Cox regression investigated the dementia risk associated with alcohol use in older adults aged over 60 years. Additional analyses assessed the alcohol–dementia relationship in the sample stratified by sex and by continent. Participants included 24 478 community dwelling individuals without a history of dementia at baseline and at least one follow-up dementia assessment. The main outcome measure was all-cause dementia as determined by clinical interview. Results: At baseline, the mean age across studies was 71.8 (standard deviation = 7.5, range = 60–102 years), 14 260 (58.3%) were female and 13 269 (54.2%) were current drinkers. During 151 636 person-years of follow-up, there were 2124 incident cases of dementia (14.0 per 1000 person-years). When compared with abstainers, the risk for dementia was lower in occasional [hazard ratio (HR) = 0.78; 95% confidence interval (CI) = 0.68–0.89], light–moderate (HR = 0.78; 95% CI = 0.70–0.87) and moderate–heavy drinkers (HR = 0.62; 95% CI = 0.51–0.77). There was no evidence of differences between life-time abstainers and former drinkers in terms of dementia risk (HR = 0.98; 95% CI = 0.81–1.18). In dose–response analyses, moderate drinking up to 40 g/day was associated with a lower risk of dementia when compared with lif-time abstaining. Among current drinkers, there was no consistent evidence for differences in terms of dementia risk. Results were similar when the sample was stratified by sex. When analysed at the continent level, there was considerable heterogeneity in the alcohol–dementia relationship. Conclusions: Abstinence from alcohol appears to be associated with an increased risk for all-cause dementia. Among current drinkers, there appears to be no consistent evidence to suggest that the amount of alcohol consumed in later life is associated with dementia risk.

Published
2023

10. Lacutamab in patients with advanced mycosis fungoides according to KIR3DL2 expression: stage 1 results from the TELLOMAK phase 2 trial

Author

Bagot, M, primary, Muller, M, additional, Kim, YH, additional, Ortiz-Romero, PL, additional, Zinzani, PL, additional, Beylot-Barry, M, additional, Dalle, S, additional, Jacobsen, E, additional, Combalia, A, additional, Huen, A, additional, Mehta-Shah, N, additional, Khodadoust, MS, additional, Viotti, J, additional, Paiva, C, additional, and Porcu, P, additional

Published
2022
Full Text
View/download PDF

14. P1131: POST HOC ANALYSIS OF PATIENTS WITH HIGHLY PROLIFERATIVE VARIANTS OF MANTLE CELL LYMPHOMA TREATED WITH ACALABRUTINIB

Author

Le Gouill, S., primary, Długosz-Danecka, M., additional, Rule, S., additional, Luigi Zinzani, P., additional, Goy, A., additional, Smith, S. D., additional, Doorduijn, J. K., additional, Panizo, C., additional, Shah, B., additional, Davies, A., additional, Eek, R., additional, Jacobsen, E., additional, Kater, A. P., additional, Robak, T., additional, Jain, P., additional, Calvo, R., additional, Yang, H., additional, and Wang, M., additional

Published
2022
Full Text
View/download PDF

15. P1172: DUVELISIB IN PATIENTS WITH RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMA FROM THE PHASE 2 PRIMO TRIAL: UPDATED EXPANSION PHASE ANALYSIS

Author

Zinzani, P. L., primary, Zain, J., additional, Mead, M., additional, Casulo, C., additional, Jacobsen, E. D., additional, Gritti, G., additional, Pinter-Brown, L., additional, Isutzu, K., additional, Cohan, D., additional, Daugherty, M., additional, Brammer, J. E., additional, Mehta-Shah, N., additional, Pro, B., additional, and Horwitz, S. M., additional

Published
2022
Full Text
View/download PDF

16. P674: UPDATED RESULTS OF A PHASE 1B STUDY OF IBRUTINIB (IBR) PLUS OBINUTUZUMAB (OBIN) IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

Author

Ryan, C., primary, Brander, D., additional, Barr, P., additional, Tyekucheva, S., additional, Ren, Y., additional, Hackett, L., additional, McDonough, M., additional, Pena Del Aguila, K., additional, McEwan, M., additional, Collins, M., additional, Abramson, J., additional, Jacobsen, E., additional, LaCasce, A., additional, Fisher, D., additional, Brown, J., additional, and Davids, M., additional

Published
2022
Full Text
View/download PDF

17. Associations between social connections and cognition: a global collaborative individual participant data meta-analysis

Author

Samtani, S., Mahalingam, G., Lam, B.C.P., Lipnicki, D.M., Lima-Costa, M.F., Blay, S.L., Castro-Costa, E., Shifu, X., Guerchet, M., Preux, P.M., Gbessemehlan, A., Skoog, I., Najar, J., Sterner, T. Rydberg, Scarmeas, N., Kim, K.W., Riedel-Heller, S., Röhr, S., Pabst, A., Shahar, S., Numbers, K., Ganguli, M., Jacobsen, E., Hughes, T.F., Crowe, M., Ng, T.P., Maddock, J., Marseglia, A., Melis, R.J.F., Szcześniak, D., Wiegelmann, H., Vernooij-Dassen, M.J.F.J., Jeon, Y.H., Sachdev, P.S., Brodaty, H., Samtani, S., Mahalingam, G., Lam, B.C.P., Lipnicki, D.M., Lima-Costa, M.F., Blay, S.L., Castro-Costa, E., Shifu, X., Guerchet, M., Preux, P.M., Gbessemehlan, A., Skoog, I., Najar, J., Sterner, T. Rydberg, Scarmeas, N., Kim, K.W., Riedel-Heller, S., Röhr, S., Pabst, A., Shahar, S., Numbers, K., Ganguli, M., Jacobsen, E., Hughes, T.F., Crowe, M., Ng, T.P., Maddock, J., Marseglia, A., Melis, R.J.F., Szcześniak, D., Wiegelmann, H., Vernooij-Dassen, M.J.F.J., Jeon, Y.H., Sachdev, P.S., and Brodaty, H.

Abstract

Item does not contain fulltext, BACKGROUND: Poor social connections (eg, small networks, infrequent interactions, and loneliness) are modifiable risk factors for cognitive decline. Existing meta-analyses are limited by reporting aggregate responses, a focus on global cognition, and combining social measures into single constructs. We aimed to investigate the association between social connection markers and the rate of annual change in cognition (ie, global and domain-specific), as well as sex differences, using an individual participant data meta-analysis. METHODS: We harmonised data from 13 longitudinal cohort studies of ageing in North America, South America, Europe, Africa, Asia, and Australia. Studies were eligible for inclusion if they had baseline data for social connection markers and at least two waves of cognitive scores. Follow-up periods ranged from 0 years to 15 years across cohorts. We included participants with cognitive data for at least two waves and social connection data for at least one wave. We then identified and excluded people with dementia at baseline. Primary outcomes were annual rates of change in global cognition and cognitive domain scores over time until final follow-up within each cohort study analysed by use of an individual participant data meta-analysis. Linear mixed models within cohorts used baseline social connection markers as predictors of the primary outcomes. Effects were pooled in two stages using random-effects meta-analyses. We assessed the primary outcomes in the main (partially adjusted) and fully adjusted models. Partially adjusted models controlled for age, sex, and education; fully adjusted models additionally controlled for diabetes, hypertension, smoking, cardiovascular risk, and depression. FINDINGS: Of the 40 006 participants in the 13 cohort studies, we excluded 1392 people with dementia at baseline. 38 614 individual participants were included in our analyses. For the main models, being in a relationship or married predicted slower global cogn

Published
2022

20. Obesity & Physical Activity

Author

Schulz SVW, Jacobsen E, Prokopchuk D, Otto S, Steinacker JM, and Schulz AS

Subjects
Sports medicine, RC1200-1245
Abstract

Introduction: A stem cell transplantation (SZT) leads to considerable physical and mental strain. It is shown that physical activity helps to cope with medical therapies. In this case report, the possibilities of modern training will be described as an example.Methods: A patient with acute myeloid leukaemia (AML) has been supervised sports-medically 2x/week over one year after allogeneic SZT. In hospital she trained with very short intervals (5-10x20sec) and 2-4 weight exercises (5-10 repetitions; 2 series) according to the Borg scale (

Published
2016
Full Text
View/download PDF

25. Traitement par lacutamab des malades ayant un lymphome T cutané au stade avancé : résultats d’efficacité dans l’étude TELLOMAK en fonction de la classification ganglionnaire actualisée

Author

Bagot, M., Kim, Y.H., Ortiz-Romero, P., Zinzani, P., Beylot-Barry, M., Dalle, S., Pham-Ledard, A., Jacobsen, E., Combalia, A., Huen, A., Mehta-Sha, N., Ram-Wolff, C., Khodadoust, M., Metha, A., Dereure, O., Battistella, M., Gru, A., Moins-Teisserenc, H., Viotti, J., Paiva, C., Boyer-Chammard, A., and Porcu, P.

Published
2023
Full Text
View/download PDF

31. MATURE RESULTS FROM A PHASE II TRIAL OF BRENTUXIMAB VEDOTIN PLUS ADRIAMYCIN AND DACARBAZINE WITHOUT RADIATION IN NON‐BULKY LIMITED STAGE CLASSICAL HODGKIN LYMPHOMA

Author

Abramson, J. S., primary, Bengston, E. M., additional, Redd, R., additional, Barnes, J. A., additional, Takvorian, T., additional, Sokol, L., additional, Lansigan, F., additional, Armand, P., additional, Shah, B., additional, Jacobsen, E., additional, Martignetti, R., additional, Turba, E., additional, Metzler, S. R., additional, Patterson, V., additional, LaCasce, A. S., additional, and Bello, C. M., additional

Published
2021
Full Text
View/download PDF

32. FIRST‐IN‐HUMAN STUDY OF THE EZH1 AND EZH2 DUAL INHIBITOR VALEMETOSTAT TOSYLATE (DS‐3201B) IN PATIENTS WITH RELAPSED OR REFRACTORY NON‐HODGKIN LYMPHOMAS

Author

Ishitsuka, K, primary, Izutsu, K, additional, Maruyama, D, additional, Makita, S, additional, Jacobsen, E. D, additional, Horwitz, S, additional, Kusumoto, S, additional, Allen, P, additional, Porcu, P, additional, Imaizumi, Y, additional, Yamauchi, N, additional, Morishima, S, additional, Kawamata, T., additional, Foss, F. M, additional, Utsunomiya, A, additional, Nosaka, K, additional, Serbest, G, additional, Kato, K, additional, Adachi, N, additional, Tsukasaki, K, additional, and Tobinai, K, additional

Published
2021
Full Text
View/download PDF

33. THE COMBINATION OF DUVELISIB AND ROMIDEPSIN (DR) IS HIGHLY ACTIVE AGAINST RELAPSED/REFRACTORY PERIPHERAL T‐CELL LYMPHOMA WITH LOW RATES OF TRANSAMINITIS: FINAL RESULTS

Author

Horwitz, S. M., primary, Moskowitz, A. J., additional, Mehta‐Shah, N., additional, Jacobsen, E. D., additional, Khodadoust, M. S., additional, Ganesan, N., additional, Drill, E., additional, Hancock, H., additional, Davey, T., additional, Myskowski, P., additional, Maccaro, C., additional, Blouin, W., additional, Schwieterman, J., additional, Cathcart, E., additional, Fang, S., additional, Perez, L., additional, Ryu, S., additional, Galasso, N., additional, Straus, D., additional, Fisher, D. C., additional, Kumar, A., additional, Noy, A., additional, Falchi, L., additional, Dogan, A., additional, Kim, Y. H., additional, and Weinstock, D., additional

Published
2021
Full Text
View/download PDF

34. ACALABRUTINIB MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA: FINAL RESULTS FROM A PHASE 2 STUDY

Author

Wang, M., primary, Rule, S., additional, Zinzani, P. L., additional, Goy, A., additional, Casasnovas, O., additional, Smith, S. D., additional, Damaj, G., additional, Doorduijn, J. K., additional, Lamy, T., additional, Morschhauser, F., additional, Panizo, C., additional, Shah, B., additional, Davies, A., additional, Eek, R., additional, Dupuis, J., additional, Jacobsen, E., additional, Kater, A. P., additional, Gouill, S., additional, Oberic, L., additional, Robak, T., additional, Jain, P., additional, Calvo, R., additional, Tao, L., additional, and Dlugosz‐Danecka, M., additional

Published
2021
Full Text
View/download PDF

35. LACUTAMAB IN PATIENTS (PTS) WITH ADVANCED MYCOSIS FUNGOIDES (MF) ACCORDING TO KIR3DL2 EXPRESSION: EARLY RESULTS FROM THE TELLOMAK PHASE 2 TRIAL

Author

Bagot, M., primary, Kim, Y., additional, Zinzani, P. L., additional, Dalle, S., additional, Beylot‐barry, M., additional, Ortiz‐Romero, P. L, additional, Cambalia, A., additional, Dereure, O., additional, Mortier, L., additional, Jacobsen, E., additional, Rotolo, F., additional, Azim, H. A, additional, and Porcu, P., additional

Published
2021
Full Text
View/download PDF

36. Cost-effectiveness of bariatric surgery and non-surgical weight management programmes for adults with severe obesity: a decision analysis model

Author

Boyers, D., Retat, L., Jacobsen, E., Avenell, A., Aveyard, P., Corbould, E., Jaccard, A., Cooper, D., Robertson, C., Aceves-Martins, M., Xu, B, Skea, Z., Bruin, M. de, Boyers, D., Retat, L., Jacobsen, E., Avenell, A., Aveyard, P., Corbould, E., Jaccard, A., Cooper, D., Robertson, C., Aceves-Martins, M., Xu, B, Skea, Z., and Bruin, M. de

Abstract

Item does not contain fulltext, OBJECTIVES: To determine the most cost-effective weight management programmes (WMPs) for adults, in England with severe obesity (BMI ≥ 35 kg/m(2)), who are more at risk of obesity related diseases. METHODS: An economic evaluation of five different WMPs: 1) low intensity (WMP1); 2) very low calorie diets (VLCD) added to WMP1; 3) moderate intensity (WMP2); 4) high intensity (Look AHEAD); and 5) Roux-en-Y gastric bypass (RYGB) surgery, all compared to a baseline scenario representing no WMP. We also compare a VLCD added to WMP1 vs. WMP1 alone. A microsimulation decision analysis model was used to extrapolate the impact of changes in BMI, obtained from a systematic review and meta-analysis of randomised controlled trials (RCTs) of WMPs and bariatric surgery, on long-term risks of obesity related disease, costs, quality adjusted life years (QALYs) and incremental cost-effectiveness ratios (ICERs) measured as incremental cost per QALY gained over a 30-year time horizon from a UK National Health Service (NHS) perspective. Sensitivity analyses explored the impact of long-term weight regain assumptions on results. RESULTS: RYGB was the most costly intervention but also generated the lowest incidence of obesity related disease and hence the highest QALY gains. Base case ICERs for WMP1, a VLCD added to WMP1, WMP2, Look AHEAD, and RYGB compared to no WMP were £557, £6628, £1540, £23,725 and £10,126 per QALY gained respectively. Adding a VLCD to WMP1 generated an ICER of over £121,000 per QALY compared to WMP1 alone. Sensitivity analysis found that all ICERs were sensitive to the modelled base case, five year post intervention cessation, weight regain assumption. CONCLUSIONS: RYGB surgery was the most effective and cost-effective use of scarce NHS funding resources. However, where fixed healthcare budgets or patient preferences exclude surgery as an option, a standard 12 week behavioural WMP (WMP1) was the next most cost-effective intervention.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results